New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
about
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerAndrogen receptor (AR) in cardiovascular diseasesMechanisms of resistance in castration-resistant prostate cancer (CRPC)Prostate cancer stem cells: the role of androgen and estrogen receptorsBiologic and clinical significance of androgen receptor variants in castration resistant prostate cancerCholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cellsNew therapy via targeting androgen receptor in monocytes/macrophages to battle atherosclerosis.Inhibitor of differentiation 4 (ID4) inactivation promotes de novo steroidogenesis and castration-resistant prostate cancer.Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variantsInfiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasion via altering the CCL5/HIF2α/androgen receptor signals.Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.Determination of androgen receptor degradation enhancer ASC-J9(®) in mouse sera and organs with liquid chromatography tandem mass spectrometry.Androgen/androgen receptor axis maintains and promotes cancer cell stemness through direct activation of Nanog transcription in hepatocellular carcinoma.New therapy with ASC-J9® to suppress the prostatitis via altering the cytokine CCL2 signals.Concise review: androgen receptor differential roles in stem/progenitor cells including prostate, embryonic, stromal, and hematopoietic lineages.Targeting the androgen receptor in prostate cancer.Natural product and natural product derived drugs in clinical trials.Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer.Leading causes of castration-resistant prostate cancer.Are androgen receptor variants a substitute for the full-length receptor?Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9(®) to Suppress Enzalutamide-resistant Prostate Cancer Progression.Sorafenib with ASC-J9® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.Biological and pharmacological evaluation of dimethoxycurcumin: A metabolically stable curcumin analogue with a promising therapeutic potential.Recent progress on curcumin-based therapeutics: a patent review (2012-2016). Part II: curcumin derivatives in cancer and neurodegeneration.Novel insights into chromosomal conformations in cancer.Quantitative and correlative biodistribution analysis of 89Zr-labeled mesoporous silica nanoparticles intravenously injected into tumor-bearing mice.Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.
P2860
Q26750620-85978034-7A54-4015-AE2C-ED1ACEC9A190Q26771962-09A3ED87-7BF5-4CC6-92C3-A32EBFF2A9CBQ26774221-DF3E6237-01B8-4DC4-9FE5-D75A7B08FDA8Q26778415-0E956089-6FA7-4B00-8C8F-46131B345C2DQ26858922-171C5D58-E02A-4C7A-835A-E703B10614EDQ28829206-255316E4-8994-4343-A71D-14292B6B6B2EQ33842431-A850065E-8333-42EA-B0B0-1276DA632A9CQ33977414-7C63FF29-0C70-4ABF-89AD-CD7E93D99514Q34194760-B148EDF5-59FB-4D25-8F18-7CDECED70AFFQ36087132-73A9D6D9-D223-49FA-87A1-4A34E87DBDDEQ36413827-4E249644-2C49-4AB0-93BE-74E318AF6F6AQ36439816-0358F87D-552D-4928-B0FF-2F63A34196C3Q36603335-12BB90CA-C698-49CC-B45D-0AC64DC99CBBQ37000514-8BD87580-1DEE-42D7-8F7E-9FB879A08121Q37148218-3FD650CF-DF77-46CD-A5A9-5D8B9FF507E3Q37207618-3AA556B4-7274-446B-BE6D-8188A77A0843Q37270422-96015D9B-12B9-494F-A6B6-8D89536D4152Q37376793-074CB9C8-463C-43E6-ADD2-7FFA2328676FQ37392841-F7F1E513-4663-4FEF-8CD0-FC65C693178AQ37687068-94A998E8-CAD4-40DB-B5B1-F54E9E512B6EQ38205189-CB64CC26-6801-45AD-88F7-F6F5A9618C1AQ38217060-231C6B1E-3765-4F32-A95F-AA3E9EB2F833Q38247457-4A898899-7B09-4375-AEB5-937480A449FEQ38272331-DAF2DD57-DA94-4426-8A9D-D3CD7BFAC1B9Q38341864-466ED3F8-D45A-45CE-BF01-C4A180337D1CQ38350089-02787D5B-191D-4325-A6A6-1BAA9568E609Q38681329-016D4A55-D476-4E7B-885E-470F2E4C6A48Q38743727-AAF059F2-A9D3-4DD9-8216-1F50C51DDDF2Q38780353-6371AB52-C6E8-4D8A-8F93-A7D184E5636FQ39361638-6F1183F1-1263-482B-B443-FDF29B70FE1EQ47098649-A3FB6E91-2775-4EE3-8245-FC317D946252Q48211125-7A206B59-3A46-48F3-9FBC-E1A9D98A2651Q53170699-A43BA6C2-D68B-4BE4-9E2C-3FF5BA07F838Q55331819-7A1939EB-6BFF-43B0-8D82-509FB64F4C9D
P2860
New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
New therapeutic approach to su ...... r in selective prostate cells.
@ast
New therapeutic approach to su ...... r in selective prostate cells.
@en
type
label
New therapeutic approach to su ...... r in selective prostate cells.
@ast
New therapeutic approach to su ...... r in selective prostate cells.
@en
prefLabel
New therapeutic approach to su ...... r in selective prostate cells.
@ast
New therapeutic approach to su ...... r in selective prostate cells.
@en
P2093
P2860
P1476
New therapeutic approach to su ...... r in selective prostate cells.
@en
P2093
Chawnshang Chang
Chin-Ying Chung
Chiung-Kuei Huang
Kuo-Pao Lai
Shinichi Yamashita
Shuyuan Yeh
Soo Ok Lee
Yu-Jia Chang
P2860
P304
P356
10.1016/J.AJPATH.2012.10.029
P407
P577
2012-12-04T00:00:00Z